FDA warned Fox Pharma LLC that it sells unapproved injectable lipolytic drugs online.
What happened
In January 2025, FDA reviewed Fox Pharma LLC’s website and social media sites and found that they offered injectable lipolytic products for sale in the United States. FDA said the products are unapproved new drugs because no FDA-approved application is in effect for them, and the website and social media claims establish they are intended as drugs.
What FDA found
The company offered injectable lipolytic products for sale in the U.S. without FDA-approved applications.
Sections 505(a) and 301(d), FD&C Act (21 U.S.C. 355(a), 331(d))FDA treated the products as “new drugs” because they are not generally recognized as safe and effective for the claimed uses.
Section 201(p), FD&C Act (21 U.S.C. 321(p))Website and social media claims, such as fat reduction and obesity treatment, show the products are intended as drugs for human use.
Section 201(g)(1), FD&C Act (21 U.S.C. 321(g)(1))
What FDA wants
FDA asks Fox Pharma LLC to notify it in writing within fifteen working days of the steps taken to correct the violations and prevent recurrence, with related documentation. If corrective action cannot be completed in that time, the company must state the reason and when it will be completed.
Who should pay attention
- online sellers of injectable cosmetic or weight-loss drugs
- clinics and med spas considering these products
- distributors and buyers of imported lipolytic injectables
This is a summary. Read the original letter on fda.gov.